Adding Darolutamide to ADT May Reduce Hospitalizations But Longer Stays in mHSPC
January 25th 2024Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.
Ruxolitinib Confers Improved Control of Steroid Refractor/Dependent cGVHD
December 11th 2023The 3-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid refractory or dependent chronic graft-versus-host disease benefited more with ruxolitinib compared with best available treatment.
Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response
December 10th 2023Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation resulted in lower relapse rates and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.
Outpatient CAR T-Cell Therapy Process Improved by Virtual Care Platform
December 10th 2023Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.
Novel Therapeutic Targets Represent Unmet Need in Translocation RCC
November 10th 2023An expert discussed how recent studies in patients with translocation RCC, a rare type of RCC, have demonstrated that the disease responds well to immune checkpoint inhibitors, but more focus is needed on novel targets to treat it.
Teclistamab Follow-Up Data Yields Consistent Results in Relapsed/Refractory Multiple Myeloma
June 9th 2023At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.
Promising ICIS Are Explored in Sarcoma, But Disparate Histologies Are Challenging
March 22nd 2022Patients with sarcoma may respond to treatment with immune checkpoint inhibitors, but identifying patients who are most likely to respond to this therapy is an ongoing obstacle and suggests the need for further research.
Daratumumab Combination Therapy Established Standard of Care for Newly Diagnosed Multiple Myeloma
October 4th 2021A recent presentation during the 18th International Myeloma Workshop focused on updated efficacy and safety data for daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone after nearly 5 years of median follow-up in the phase 3 MAIA study.
Fixed-Duration Ibrutinib/Venetoclax Shows Greater PFS in CLL
June 12th 2021A fixed duration of ibrutinib plus venetoclax led to a significant progression-free survival benefit over chlorambucil plus obinutuzumab as frontline treatment in patients with chronic lymphocytic leukemia, according to a primary analysis of the phase 3 GLOW study presented at the European Hematology Association 2021 Virtual Congress.
Durable Responses Seen with Cilta-Cel at 18 Months in Relapsed/Refractory Multiple Myeloma
June 8th 2021Sustained efficacy and durable responses was seen with Ciltacabtagene autoleucel, an investigational B-cell maturation antigen-directed CAR T-cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma.
Polatuzumab With Rituximab and Lenalidomide Shown Safe and Effective for Relapsed/Refractory DLBCL
June 5th 2021In patients with relapsed/refractory diffuse large B-cell lymphoma treated with the triplet combinaton of polatuzumab vedotin, rituximab and lenalidomide, therapy was considered to be safe and effective.
Lower Medicaid Eligibility May Equate to Worse Cancer Survival Rates
May 19th 2021Policies may be needed to expand Medicaid access to patients, after investigators found worse long-term survival outcomes for patients who lived in states with lower income eligibility rather than higher income eligibility.
Higher Lenvatinib Dose May Improve HRQoL in RCC
April 2nd 2021The standard dose of lenvatinib, 18 mg per day, demonstrated an improved health-related quality of life and a longer time to deterioration over a lower starting dose of lenvatinib, 14 mg per day, in patients with renal cell carcinoma, according to secondary results from a phase 2 trial.